Genmab A/S (GMAB) Q1 2022 Earnings Call Transcript

For the period ending March 31, 2022

May 11, 2022 12:00 p.m. ET

Prepared Remarks

Questions and Answers

Call Participants

Prepared Remarks:

Operator

Hello, and welcome to the Genmab Q1 2022 Conference Call. Throughout the call, all participants will be in listen only mode. And afterwards, there will be a question-and-answer session. Just to remind you, this conference call is being recorded.

During the telephone conference, you may be presented with forward-looking statements that include words such as believes, anticipates, plans or expects. Actual results may differ materially. For example, as a result of delayed or unsuccessful development projects. Genmab is not under any obligation to update statements regarding the future, nor to confirm such statements in relation to actual results, unless this is required by law.

Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab going forward. Please refer to our website for more information on Genmab and our privacy policy.

Today, I’m pleased to present Jan van de Winkel. Please go ahead with your meeting.

Jan van de Winkel

Hello and welcome to the Genmab conference call to discuss the Company’s financial results for the period ended March 31, 2022. With me today to present these results is our CFO, Anthony Pagano.

Let’s move to Slide 2. As already said, we will be making forward-looking statements. So, please keep that in mind as we go through this call.

Let’s move to Slide 3. Genmab has a innovation-based culture, and collaborations and partnerships have always been part of our DNA. During today’s presentation, we will reference some of the products being developed under these strategic collaborations, and this slide acknowledges those relationships.

Let’s move to Slide 4. I would like begin with a reminder that thanks to a consistent and solid track record of success, our world class team and our strong financial foundation, we have never been in a better position to achieve our ambitious vision of transforming cancer treatment. During the first quarter of 2022, we continue to build on this foundation with multiple advancements in our pipeline.

So now let's move to Slide 5, and take a look at some of the recent achievements and updates. I'm excited to start with the fact that last month we and AbbVie announced top-line results from the first cohort of the Phase 1/2 study of epcoritamab in patients with relapsed or refractory large B-cell lymphoma, who have received at least two prior lines of systemic therapy, including 38.9% who received prior treatment with CAR-T therapy.